Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001104659-24-129622·InMed Pharmaceuticals Inc.
Schedule 13G ownership disclosure
INMED PHARMACEUTICALS INC
Common Shares · CUSIP: 457637601
Event date: 2024-12-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- YA II PN, Ltd.
Shares: 80,372.00 · Class: 9.99%
- YA Global Investments II (U.S.), LP
Shares: 80,372.00 · Class: 9.99%
- Yorkville Advisors Global, LP
Shares: 80,372.00 · Class: 9.99%
- Yorkville Advisors Global II, LLC
Shares: 80,372.00 · Class: 9.99%
- YA II GP, LP
Shares: 80,372.00 · Class: 9.99%
- YAII GP II, LLC
Shares: 80,372.00 · Class: 9.99%
- Mark Angelo
Shares: 80,372.00 · Class: 9.99%
- SC-Sigma Global Partners, LP
Shares: 80,372.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-24-129622
- Form type
- SCHEDULE 13G
- Filer
- InMed Pharmaceuticals Inc.
- CIK
- CIK 1728328
- Filed
- Dec 18, 2024
- Reporting period
- Dec 13, 2024
- Description
- Schedule 13G beneficial ownership